Table 5.
Diagnostic performance of screening tests regarding detection of hemostatic abnormalities
| Screening tests (reference range) | All patients (n = 335), Abnormal screening test results n (%) | Range of screening test abnormalities (sec, min, score) | Sensitivity % (95% CI) | Specificity % (95% CI) | PPV % (95% CI) | NPV % (95% CI) |
|---|---|---|---|---|---|---|
| aPTT (>32 s) | 3 (0.9) | 34 | 5.9 (0.3‐15) | 99 (99‐100) | 33 (1.8‐87) | 95 (95‐96) |
| PT (>11.5 s) | 5 (1.5) | 11.8‐12.2 | 63 (32‐63) | 100 (99‐100) | 100 (50‐100) | 99 (98‐99) |
| TT (>21 s) | 0 (0) | — | NA | 100 | NA | 100 |
| PFA‐epi (CT>160 s) | 19 (5.7) | 161‐300 | 10 (1.8‐30) | 93 (93‐95) | 8.7 (1.5‐2.7) | 94 (94‐95) |
| PFA‐ADP (CT>118 s) | 23 (6.9) | 119‐300 | 5.0 (0.3‐24) | 94 (94‐96) | 5.3 (0.3‐25) | 94 (94‐95) |
| ELT (<40 min)a | 1 (0.3) | 15 | 0 (0‐91) | 99.7 (99‐100) | 0 (0‐91) | 99.7 (99‐100) |
|
ISTH‐BAT females (>5), n = 216 ISTH‐BAT males (>3), n = 119 |
62 (29) 21 (18) |
0‐16 0‐14 |
31 (12‐58) 27 (9.2‐52) |
72 (70‐74) 84 (81‐87) |
8.1 (3.2‐15) 19 (6.6‐37) |
93 (91‐96) 89 (86‐93) |
CI; confidence interval. CT; Closure Time. NPV; negative predictive value. PPV; positive predictive value.
Diagnostic performance of the prothrombin time (PT) for detecting reduced FII, V, VII, and X activity levels, activated partial prothrombin time (aPTT) for detecting reduced FII, V, VIII, IX, X, XI, and XII activity levels, thrombin time (TT) for reduced fibrinogen levels (and dysfunction), the platelet function analyser (PFA) for detecting reduced von Willebrand factor antigen/activity or platelet function defects, the euglobulin lysis time for high tPA levels, and the ISTH‐BAT for any kind of hemostatic abnormality. See Supplemental Digital Content Table S2 for cross tables. Hospital reference ranges were applied, except for ELT.
Reference ranges were established using EP‐evaluator; nonparametric Index Method.